Alcon’s AcrySof IQ PanOptix Receives the US FDA’s Approval as the First Trifocal Lens for Patients Undergoing Cataract Surgery in the US

 Alcon’s AcrySof IQ PanOptix Receives the US FDA’s Approval as the First Trifocal Lens for Patients Undergoing Cataract Surgery in the US

Alcon’s AcrySof IQ PanOptix Receives the US FDA’s Approval as the First Trifocal Lens for Patients Undergoing Cataract Surgery in the US

Shots:

  • Alcon launches PanOptix Trifocal Intraocular Lens (IOL) to delivers a combination of near, intermediate and distance vision while reducing the need for glasses. Alcon plans to train US Ophthalmologist and to begin patient awareness program in H1’20
  • The approval of PanOptix is based on a pivotal study conducted at 12 sites in the US, demonstrated high patient satisfaction with >99% patients saying they would choose the same lens again
  • The AcrySof IQ PanOptix Trifocal IOL is a multifocal used to focus images clearly onto the retina to allow clear vision after the cataract removal, utilizes ENLIGHTEN optical technology to optimize intermediate vision without compromising near and distance vision and is available in spherical and toric designs

Click here to­ read full press release/ article | Ref: Alcon | Image: CODET Vision Institute

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post